Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free IPSC Stock Alerts

Century Therapeutics (IPSC) Financials

Century Therapeutics logo
$2.43 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$2.42 -0.01 (-0.21%)
As of 07/2/2026 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Century Therapeutics

Annual Income Statements for Century Therapeutics

This table shows Century Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -54 -96 -131 -137 -127 -9.58
Consolidated Net Income / (Loss)		 -54 -96 -131 -137 -127 -9.58
Net Income / (Loss) Continuing Operations		 -54 -96 -131 -137 -127 -9.58
Total Pre-Tax Income 		-54 -96 -131 -135 -125 -9.65
Total Operating Income		 -54 -95 -134 -147 -138 -17
Total Gross Profit		 0.00 0.00 5.20 2.24 6.59 109
Total Revenue		 0.00 0.00 5.20 2.24 6.59 109
Operating Revenue		 - 0.00 5.20 2.24 6.59 109
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 54 95 139 149 145 126
Selling, General & Admin Expense		 9.50 19 32 35 33 24
Research & Development Expense		 44 76 107 98 107 96
Impairment Charge		 - - 0.00 16 4.33 6.76
Total Other Income / (Expense), net		 0.65 -1.80 2.99 12 13 7.62
Interest & Investment Income		 - - - 13 13 7.35
Other Income / (Expense), net		 0.65 -1.80 2.99 -0.38 0.35 0.28
Income Tax Expense		 0.00 0.04 0.09 1.88 1.79 -0.07
Basic Earnings per Share		 ($7.16) ($2.96) ($2.27) ($2.30) ($1.61) ($0.14)
Weighted Average Basic Shares Outstanding		 7.48M 32.39M 57.76M 59.31M 78.65M 86.56M
Diluted Earnings per Share		 ($7.16) ($2.96) ($2.96) ($2.30) ($1.61) ($0.14)
Weighted Average Diluted Shares Outstanding		 7.48M 32.39M 32.39M 59.31M 78.65M 86.56M
Weighted Average Basic & Diluted Shares Outstanding		 - 58.82M 59.17M 64.82M 86.05M 179.72M

Quarterly Income Statements for Century Therapeutics

This table shows Century Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -33 -39 -28 -31 -31 -36 77 -33 -34 -19 -22
Consolidated Net Income / (Loss)		 -33 -39 -28 -31 -31 -36 77 -33 -34 -19 -22
Net Income / (Loss) Continuing Operations		 -33 -39 -28 -31 -31 -36 77 -33 -34 -19 -22
Total Pre-Tax Income 		-32 -40 -28 -31 -31 -34 0.00 -33 -34 -19 0.00
Total Operating Income		 -36 -44 -31 -35 -35 -37 74 -35 -36 -21 -24
Total Gross Profit		 0.15 0.27 0.86 0.77 0.79 4.17 109 0.00 0.00 - 0.00
Total Revenue		 0.15 0.27 0.86 0.77 0.79 4.17 109 0.00 0.00 - 0.00
Operating Revenue		 0.15 0.27 0.86 0.77 0.79 4.17 109 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 36 44 32 36 36 41 35 35 36 21 24
Selling, General & Admin Expense		 8.99 8.59 8.74 8.31 8.35 7.75 8.41 7.81 6.84 0.96 6.58
Research & Development Expense		 27 23 23 27 27 29 27 27 23 20 17
Total Other Income / (Expense), net		 3.50 3.50 3.25 3.57 3.56 2.99 2.38 2.12 1.70 1.41 2.04
Interest & Investment Income		 3.49 3.51 3.24 3.58 3.31 2.88 2.42 2.01 1.61 1.31 2.02
Other Income / (Expense), net		 0.01 -0.02 0.01 -0.01 0.25 0.11 -0.04 0.11 0.10 0.10 0.02
Basic Earnings per Share		 ($0.55) ($0.66) ($0.45) ($0.38) ($0.37) ($0.41) $0.89 ($0.38) ($0.40) ($0.25) ($0.11)
Weighted Average Basic Shares Outstanding		 59.45M 59.31M 62.30M 82.09M 84.70M 78.65M 86.02M 86.24M 86.46M 86.56M 193.47M
Diluted Earnings per Share		 ($0.55) - ($0.45) ($0.38) ($0.37) - $0.89 ($0.38) ($0.40) ($0.25) ($0.11)
Weighted Average Diluted Shares Outstanding		 59.45M 59.31M 62.30M 82.09M 84.70M 78.65M 86.10M 86.24M 86.46M 86.56M 193.47M
Weighted Average Basic & Diluted Shares Outstanding		 59.83M 64.82M 82.85M 84.72M 85.03M 86.05M 86.16M 86.39M 87.31M 179.72M 180.35M

Annual Cash Flow Statements for Century Therapeutics

This table details how cash moves in and out of Century Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -16 30 28 -37 12 3.80
Net Cash From Operating Activities		 -41 -89 14 -88 -110 -104
Net Cash From Continuing Operating Activities		 -41 -89 14 -88 -110 -104
Net Income / (Loss) Continuing Operations		 -54 -96 -131 -137 -127 -9.58
Consolidated Net Income / (Loss)		 -54 -96 -131 -137 -127 -9.58
Depreciation Expense		 1.40 3.75 8.44 13 13 13
Amortization Expense		 0.09 0.31 0.30 -3.89 -4.81 -2.36
Non-Cash Adjustments To Reconcile Net Income		 6.62 6.35 13 30 16 9.59
Changes in Operating Assets and Liabilities, net		 4.19 -3.58 123 9.16 -8.41 -115
Net Cash From Investing Activities		 -23 -298 -13 61 47 108
Net Cash From Continuing Investing Activities		 -23 -298 -13 61 47 108
Purchase of Property, Plant & Equipment		 -9.83 -45 -31 -14 -0.15 -0.85
Acquisitions		 -4.72 - - 0.00 -9.61 0.00
Purchase of Investments		 -50 -330 -254 -209 -120 -51
Sale and/or Maturity of Investments		 42 77 271 284 177 160
Net Cash From Financing Activities		 48 418 27 -9.73 75 0.17
Net Cash From Continuing Financing Activities		 48 418 27 -9.73 75 0.17
Repayment of Debt		 -0.14 - 0.00 -10 57 0.00
Issuance of Common Equity		 0.00 222 27 0.52 18 0.17
Cash Income Taxes Paid		 - 0.01 0.00 2.52 0.50 3.89

Quarterly Cash Flow Statements for Century Therapeutics

This table details how cash moves in and out of Century Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -9.13 -7.98 -0.51 -4.50 11 5.78 -6.57 4.95 -0.91 6.34 -11
Net Cash From Operating Activities		 -14 -26 -30 -27 -28 -24 -35 -28 -26 -16 -25
Net Cash From Continuing Operating Activities		 -14 -26 -30 -27 -28 -25 -35 -28 -26 -16 -25
Net Income / (Loss) Continuing Operations		 -33 -39 -28 -31 -31 -36 77 -33 -34 -19 -22
Consolidated Net Income / (Loss)		 -33 -39 -28 -31 -31 -36 77 -33 -34 -19 -22
Depreciation Expense		 3.35 3.55 3.23 3.46 3.30 3.32 3.22 3.20 3.13 3.55 3.00
Amortization Expense		 - -3.98 -1.12 -1.34 -1.32 -1.03 -0.85 -0.65 -0.51 -0.35 -0.21
Non-Cash Adjustments To Reconcile Net Income		 3.54 17 4.77 1.04 3.69 6.85 2.66 3.10 7.02 -3.19 0.02
Changes in Operating Assets and Liabilities, net		 12 -2.91 -9.07 0.71 -2.78 1.85 -116 -0.70 -0.80 3.09 -6.43
Net Cash From Investing Activities		 4.22 19 12 -34 39 31 28 33 25 22 -113
Net Cash From Continuing Investing Activities		 4.22 19 12 -34 39 31 28 33 25 22 -113
Purchase of Property, Plant & Equipment		 -3.27 -0.98 -0.54 -0.27 0.80 -0.15 -0.48 -0.32 -0.20 0.14 -0.58
Purchase of Investments		 -57 -9.69 -35 -54 -13 -17 -15 -9.67 -11 -16 -141
Sale and/or Maturity of Investments		 65 29 47 30 52 48 43 43 36 38 29
Net Cash From Financing Activities		 0.30 -0.36 18 57 0.27 -0.60 0.12 - - 0.05 127
Net Cash From Continuing Financing Activities		 0.30 -0.36 18 57 0.27 -0.60 0.12 - - 0.05 127
Repayment of Debt		 - - - - - - 0.00 - - - 126
Issuance of Common Equity		 0.30 -0.36 18 0.10 0.27 -0.60 0.12 - - 0.05 0.20
Cash Income Taxes Paid		 - 1.61 0.00 0.19 -0.18 0.49 0.00 -0.00 - 3.89 0.00

Annual Balance Sheets for Century Therapeutics

This table presents Century Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 107 437 487 361 353 224
Total Current Assets		 79 228 320 177 194 121
Cash & Equivalents		 27 56 84 47 58 62
Short-Term Investments		 49 166 231 125 131 55
Prepaid Expenses		 2.26 4.77 4.00 4.26 4.76 3.66
Plant, Property, & Equipment, net		 15 58 83 72 62 50
Total Noncurrent Assets		 13 151 84 112 97 53
Long-Term Investments		 1.05 136 52 89 31 0.00
Intangible Assets		 - - - 0.00 34 34
Other Noncurrent Operating Assets		 12 15 32 23 32 19
Total Liabilities & Shareholders' Equity		 107 437 487 361 353 224
Total Liabilities		 33 41 184 176 192 65
Total Current Liabilities		 12 16 30 18 130 20
Short-Term Debt		 0.00 1.04 6.50 - 0.00 3.76
Accounts Payable		 8.08 7.60 5.45 2.74 3.08 4.77
Accrued Expenses		 4.03 6.04 9.84 10 17 12
Customer Deposits		 0.00 0.98 0.87 0.58 0.08 0.02
Total Noncurrent Liabilities		 21 25 154 158 62 45
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 0.00 4.37 4.30
Other Noncurrent Operating Liabilities		 12 17 39 47 58 40
Total Equity & Noncontrolling Interests		 -106 396 303 185 161 159
Total Preferred & Common Equity		 -106 396 303 185 161 159
Total Common Equity		 -106 396 303 185 161 159
Common Stock		 218 785 824 840 943 951
Retained Earnings		 -292 -388 -519 -656 -782 -792
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.65 -2.46 0.11 0.32 0.03

Quarterly Balance Sheets for Century Therapeutics

This table presents Century Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 398 349 416 389 316 285 245 327
Total Current Assets		 174 200 203 206 170 160 138 139
Cash & Equivalents		 55 47 41 53 52 57 56 51
Short-Term Investments		 114 145 155 146 113 99 77 84
Prepaid Expenses		 4.20 7.80 7.08 7.90 4.51 4.33 4.96 4.24
Plant, Property, & Equipment, net		 82 69 69 65 60 57 54 48
Total Noncurrent Assets		 142 80 144 117 86 68 53 140
Long-Term Investments		 115 58 73 47 21 2.69 0.00 82
Intangible Assets		 - - 33 34 34 34 34 34
Other Noncurrent Operating Assets		 27 22 32 32 32 31 19 24
Total Liabilities & Shareholders' Equity		 398 349 416 389 316 285 245 327
Total Liabilities		 178 171 194 193 75 75 68 62
Total Current Liabilities		 20 16 19 20 15 15 22 14
Short-Term Debt		 0.00 - - - - - 8.34 1.94
Accounts Payable		 5.93 3.43 3.36 2.60 3.57 3.21 2.62 3.15
Accrued Expenses		 9.93 7.53 11 13 11 12 11 8.48
Customer Deposits		 0.71 0.49 0.35 0.21 0.00 0.02 0.02 0.00
Total Noncurrent Liabilities		 158 155 175 173 61 60 46 48
Noncurrent Deferred & Payable Income Tax Liabilities		 - - 3.37 3.50 4.37 4.37 4.37 4.30
Other Noncurrent Operating Liabilities		 46 44 62 60 56 55 42 44
Total Equity & Noncontrolling Interests		 219 178 222 196 240 210 176 265
Total Preferred & Common Equity		 219 178 222 196 240 210 176 265
Total Common Equity		 219 178 222 196 240 210 176 265
Common Stock		 837 862 937 941 946 948 949 1,079
Retained Earnings		 -616 -684 -715 -746 -706 -738 -773 -814
Accumulated Other Comprehensive Income / (Loss)		 -1.30 -0.24 -0.31 0.76 0.31 0.08 0.06 -0.59

Annual Metrics And Ratios for Century Therapeutics

This table displays calculated financial ratios and metrics derived from Century Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 54,641,380.00 58,974,247.00 59,834,968.00 - 87,307,091.00
DEI Adjusted Shares Outstanding		 0.00 54,641,380.00 58,974,247.00 59,834,968.00 - 87,307,091.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.75 -2.22 -2.28 - -0.11
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -57.01% 194.81% 1,556.76%
EBITDA Growth		 0.00% -78.96% -31.82% -12.84% 6.16% 95.17%
EBIT Growth		 0.00% -81.55% -35.34% -12.30% 6.22% 87.67%
NOPAT Growth		 0.00% -76.04% -41.05% -9.50% 5.74% 87.50%
Net Income Growth		 0.00% -78.86% -36.64% -4.38% 7.40% 92.43%
EPS Growth		 0.00% 58.66% 0.00% 22.30% 30.00% 91.30%
Operating Cash Flow Growth		 0.00% -115.66% 115.79% -728.72% -24.66% 5.68%
Free Cash Flow Firm Growth		 0.00% 0.00% 107.51% -1,088.71% -44.02% -1.20%
Invested Capital Growth		 0.00% 666.90% -214.74% -41.77% 23.79% 177.58%
Revenue Q/Q Growth		 0.00% 0.00% 11.14% -10.17% 145.40% -3.68%
EBITDA Q/Q Growth		 0.00% 0.00% -0.11% -13.72% -2.23% 73.73%
EBIT Q/Q Growth		 0.00% 0.00% -1.48% -9.94% -4.19% 49.45%
NOPAT Q/Q Growth		 0.00% 0.00% -4.15% -7.68% 4.48% 49.05%
Net Income Q/Q Growth		 0.00% 0.00% -2.74% -5.98% 2.56% 63.81%
EPS Q/Q Growth		 0.00% 0.00% -2,790.91% 0.00% 0.00% 53.33%
Operating Cash Flow Q/Q Growth		 0.00% -14.29% 11.45% -3.91% 1.79% 7.27%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.18% 1.91% 6.61%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.98% -18.52% -19.92% -12.24%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -2,348.57% -6,164.43% -1,962.22% -5.73%
Operating Margin		 0.00% 0.00% -2,574.17% -6,556.87% -2,096.48% -15.82%
EBIT Margin		 0.00% 0.00% -2,516.66% -6,574.00% -2,091.11% -15.57%
Profit (Net Income) Margin		 0.00% 0.00% -2,518.41% -6,115.12% -1,920.87% -8.78%
Tax Burden Percent		 100.00% 100.04% 100.07% 101.40% 101.43% 99.30%
Interest Burden Percent		 100.61% 99.07% 100.00% 91.74% 90.56% 56.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -73.04% -40.81% -37.46% -56.07% -73.14% -5.98%
Cash Return on Invested Capital (CROIC)		 0.00% -401.84% 0.00% 0.00% 0.00% -255.41%
Operating Return on Assets (OROA)		 0.00% 0.00% -28.32% -34.68% -38.60% -5.89%
Return on Assets (ROA)		 0.00% 0.00% -28.34% -32.26% -35.46% -3.32%
Return on Common Equity (ROCE)		 105.97% -25.19% -37.46% -56.07% -73.14% -5.98%
Return on Equity Simple (ROE_SIMPLE)		 50.35% -24.18% -43.25% -73.98% -78.44% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -66 -94 -103 -97 -12
NOPAT Margin		 0.00% 0.00% -1,801.92% -4,589.81% -1,467.54% -11.07%
Net Nonoperating Expense Percent (NNEP)		 -23.59% -14.14% -10.55% -11.02% -12.40% 1.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -55.52% -59.92% -7.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 612.75% 1,552.84% 503.19% 21.99%
R&D to Revenue		 0.00% 0.00% 2,061.42% 4,371.81% 1,627.62% 87.64%
Operating Expenses to Revenue		 0.00% 0.00% 2,674.17% 6,656.87% 2,196.48% 115.82%
Earnings before Interest and Taxes (EBIT)		 -53 -97 -131 -147 -138 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -52 -93 -122 -138 -129 -6.25
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.19 1.00 1.08 0.53 0.55
Price to Tangible Book Value (P/TBV)		 0.00 2.19 1.00 1.08 0.68 0.70
Price to Revenue (P/Rev)		 0.00 0.00 58.19 88.88 13.03 0.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 52.37 10.93 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.13 0.03 0.03 0.00 0.00 0.02
Long-Term Debt to Equity		 0.13 0.02 0.01 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.89 -1.01 -1.27 -1.39 -1.04
Leverage Ratio		 1.46 1.16 1.32 1.74 2.06 1.80
Compound Leverage Factor		 1.46 1.15 1.32 1.59 1.87 1.02
Debt to Total Capital		 11.61% 2.45% 3.27% 0.00% 0.00% 2.31%
Short-Term Debt to Total Capital		 0.00% 0.26% 2.08% 0.00% 0.00% 2.31%
Long-Term Debt to Total Capital		 11.61% 2.19% 1.19% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 216.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -128.23% 97.55% 96.73% 100.00% 100.00% 97.69%
Debt to EBITDA		 -0.19 -0.11 -0.08 0.00 0.00 -0.60
Net Debt to EBITDA		 1.30 3.77 2.92 0.00 0.00 18.14
Long-Term Debt to EBITDA		 -0.19 -0.10 -0.03 0.00 0.00 0.00
Debt to NOPAT		 -0.26 -0.15 -0.11 0.00 0.00 -0.31
Net Debt to NOPAT		 1.78 5.25 3.81 0.00 0.00 9.38
Long-Term Debt to NOPAT		 -0.26 -0.13 -0.04 0.00 0.00 0.00
Altman Z-Score		 -0.94 11.25 -0.67 -2.68 -3.88 -3.37
Noncontrolling Interest Sharing Ratio		 245.08% 38.28% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.51 14.57 10.72 9.92 1.50 5.97
Quick Ratio		 6.25 14.24 10.58 9.68 1.46 5.79
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -108 8.08 -80 -115 -116
Operating Cash Flow to CapEx		 -420.04% -197.91% 45.92% -643.19% -71,516.23% -12,249.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -147.91 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -163.61 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -189.04 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.01 0.02 0.38
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.07 0.03 0.10 1.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 6.18 47 -54 -77 -59 46
Invested Capital Turnover		 0.00 0.00 -1.49 -0.03 -0.10 -16.58
Increase / (Decrease) in Invested Capital		 0.00 41 -102 -23 18 104
Enterprise Value (EV)		 324 518 -55 -63 -134 -27
Market Capitalization		 211 867 303 199 86 87
Book Value per Share		 ($14.22) $7.25 $5.13 $3.09 $1.90 $1.82
Tangible Book Value per Share		 ($14.22) $7.25 $5.13 $3.09 $1.50 $1.43
Total Capital		 83 406 313 185 161 163
Total Debt		 9.64 9.94 10 0.00 0.00 3.76
Total Long-Term Debt		 9.64 8.90 3.74 0.00 0.00 0.00
Net Debt		 -67 -349 -357 -262 -220 -113
Capital Expenditures (CapEx)		 9.83 45 31 14 0.15 0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.07 -9.34 -19 -14 -125 -13
Debt-free Net Working Capital (DFNWC)		 67 214 296 159 64 104
Net Working Capital (NWC)		 67 212 290 159 64 101
Net Nonoperating Expense (NNE)		 16 29 37 34 30 -2.51
Net Nonoperating Obligations (NNO)		 -67 -349 -357 -262 -220 -113
Total Depreciation and Amortization (D&A)		 1.49 4.05 8.74 9.15 8.49 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -367.22% -608.05% -1,897.45% -11.74%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 5,701.21% 7,120.72% 975.40% 95.54%
Net Working Capital to Revenue		 0.00% 0.00% 5,576.15% 7,120.72% 975.40% 92.10%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.96) ($2.27) ($2.30) ($1.61) ($0.14)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 32.39M 57.76M 59.31M 78.65M 86.56M
Adjusted Diluted Earnings per Share		 $0.00 ($2.96) ($2.27) ($2.27) ($1.61) ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 32.39M 57.76M 57.76M 78.65M 86.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 58.82M 59.17M 64.82M 86.05M 179.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -66 -94 -91 -94 -7.35
Normalized NOPAT Margin		 0.00% 0.00% -1,801.92% -4,077.26% -1,421.57% -6.74%
Pre Tax Income Margin		 0.00% 0.00% -2,516.66% -6,030.96% -1,893.70% -8.84%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -272.09 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -189.97 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -297.53 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -215.40 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Century Therapeutics

This table displays calculated financial ratios and metrics derived from Century Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 59,765,270.00 59,834,968.00 64,817,863.00 82,847,375.00 84,715,961.00 - 86,045,033.00 86,158,758.00 86,389,098.00 87,307,091.00 179,722,750.00
DEI Adjusted Shares Outstanding		 59,765,270.00 59,834,968.00 64,817,863.00 82,847,375.00 84,715,961.00 - 86,045,033.00 86,158,758.00 86,389,098.00 87,307,091.00 179,722,750.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.55 -0.66 -0.43 -0.38 -0.37 - 0.89 -0.38 -0.40 -0.22 -0.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -93.35% -48.56% -50.29% 678.79% 434.46% 1,456.72% 12,667.72% -100.00% -100.00% 0.00% -100.00%
EBITDA Growth		 -11.60% -60.28% 0.42% -2.05% -0.92% 21.07% 362.12% 1.99% -2.59% 50.27% -127.28%
EBIT Growth		 -12.13% -43.58% 3.03% 1.41% 3.02% 15.07% 336.88% 0.62% -4.31% 44.72% -131.92%
NOPAT Growth		 -12.25% -31.39% 2.41% 0.92% 2.35% 14.80% 336.92% 0.26% -3.84% 44.60% -131.93%
Net Income Growth		 -6.41% -24.35% 10.24% 6.26% 4.57% 8.44% 372.82% -4.27% -10.24% 46.84% -128.27%
EPS Growth		 -3.77% 0.00% 0.00% 32.14% 32.73% 0.00% 297.78% 0.00% -8.11% 39.02% -112.36%
Operating Cash Flow Growth		 43.69% -14.51% -3.52% -41.98% -107.58% 7.65% -14.46% -0.95% 9.70% 33.63% 27.04%
Free Cash Flow Firm Growth		 -122.71% -110.10% 106.15% 6.94% -172.77% -460.88% -2,809.54% -307.64% -212.43% -167.33% 84.35%
Invested Capital Growth		 -18.45% -41.77% -52.15% 11.02% 24.67% 23.79% 175.86% 208.08% 206.01% 177.58% -8.96%
Revenue Q/Q Growth		 49.49% 81.08% 219.03% -9.82% 2.59% 427.43% 2,516.59% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.85% -37.02% 33.98% -11.86% 0.26% -7.16% 319.25% -141.82% -4.40% 48.05% -20.27%
EBIT Q/Q Growth		 -1.00% -22.92% 28.51% -11.08% 0.66% -7.64% 299.41% -146.60% -4.27% 42.95% -15.13%
NOPAT Q/Q Growth		 -1.57% -22.84% 28.46% -11.01% -0.10% -7.17% 298.95% -132.71% -4.21% 42.82% -14.65%
Net Income Q/Q Growth		 1.72% -20.41% 28.77% -11.21% -0.06% -15.52% 312.25% -142.50% -5.78% 44.29% -12.87%
EPS Q/Q Growth		 1.79% 0.00% 0.00% 15.56% 2.63% 0.00% 317.07% -142.70% -5.26% 37.50% 56.00%
Operating Cash Flow Q/Q Growth		 29.10% -92.18% -15.32% 9.64% -3.66% 14.50% -42.93% 20.31% 7.28% 37.16% -57.13%
Free Cash Flow Firm Q/Q Growth		 54.38% 46.51% 134.78% -1,196.33% -33.72% -9.99% -68.04% -134.96% -2.49% 5.89% 90.16%
Invested Capital Q/Q Growth		 -21.78% -18.52% 6.61% 33.98% -3.09% -19.92% 192.95% -5.93% 1.11% -12.24% 9.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -21,800.00% -16,495.90% -3,413.68% -4,234.50% -4,116.56% -836.39% 70.08% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -24,071.62% -16,329.10% -3,661.87% -4,507.78% -4,398.10% -893.67% 67.95% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -24,063.51% -16,334.70% -3,660.58% -4,509.34% -4,366.50% -891.16% 67.91% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -22,108.11% -14,700.75% -3,282.11% -4,047.60% -3,947.66% -864.60% 70.13% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.84% 97.84% 100.00% 100.07% 99.97% 105.18% 0.00% 100.00% 100.00% 99.65% 0.00%
Interest Burden Percent		 90.21% 91.98% 89.66% 89.70% 90.43% 92.25% 0.00% 94.18% 95.55% 93.63% 0.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.94% -56.07% -58.66% -55.95% -62.61% -73.14% -10.49% 0.00% 0.00% -5.98% -42.67%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -273.69% -236.90% -240.01% -255.41% -145.13%
Operating Return on Assets (OROA)		 -131.68% -86.18% -12.46% -22.09% -29.83% -16.45% 23.50% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -120.98% -77.56% -11.18% -19.83% -26.96% -15.96% 24.27% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.94% -56.07% -58.66% -55.95% -62.61% -73.14% -10.49% 0.00% 0.00% -5.98% -42.67%
Return on Equity Simple (ROE_SIMPLE)		 -58.82% 0.00% -75.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -31 -22 -24 -24 -26 52 -24 -25 -14 -17
NOPAT Margin		 -16,850.14% -11,430.37% -2,563.31% -3,155.45% -3,078.67% -625.57% 47.56% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.33% -2.83% -2.14% -2.41% -2.60% -4.14% 11.31% -3.87% -4.95% -2.83% -2.53%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.58% -12.32% -10.95% -12.44% -16.17% 21.60% -11.56% -13.69% -8.89% -6.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,071.62% 3,204.85% 1,022.57% 1,077.30% 1,055.88% 185.86% 7.70% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 18,100.00% 8,692.54% 2,739.30% 3,530.48% 3,442.23% 704.10% 24.35% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 24,171.62% 16,429.10% 3,761.87% 4,607.78% 4,498.10% 993.67% 32.05% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -36 -44 -31 -35 -35 -37 74 -35 -36 -21 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -44 -29 -33 -33 -35 77 -32 -33 -17 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.55 1.08 1.52 0.95 0.74 0.53 0.17 0.23 0.24 0.55 1.53
Price to Tangible Book Value (P/TBV)		 0.55 1.08 1.52 1.15 0.92 0.68 0.20 0.27 0.30 0.70 1.76
Price to Revenue (P/Rev)		 48.04 88.88 197.77 103.46 53.95 13.03 0.36 0.42 0.38 0.80 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 15.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.02 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.22 -1.27 -1.26 -1.21 -1.27 -1.39 -1.04 -0.99 -0.99 -1.04 -0.79
Leverage Ratio		 1.66 1.74 1.77 1.77 1.89 2.06 1.59 1.62 1.70 1.80 1.27
Compound Leverage Factor		 1.49 1.60 1.59 1.59 1.71 1.90 0.00 1.53 1.63 1.69 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.51% 2.31% 0.73%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.51% 2.31% 0.73%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 95.49% 97.69% 99.27%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.35 -0.60 -0.02
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.23 18.14 2.08
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.35 -0.31 -0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.24 9.38 2.67
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.60 -1.73 -1.45 -1.49 -1.95 -2.94 -1.07 -2.63 -3.50 -3.43 0.68
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.50 9.92 12.44 10.62 10.39 1.50 11.70 10.72 6.25 5.97 10.25
Quick Ratio		 8.29 9.68 11.95 10.25 10.00 1.46 11.39 10.43 6.03 5.79 9.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -7.92 2.76 -30 -40 -44 -75 -123 -126 -119 -12
Operating Cash Flow to CapEx		 -418.04% -2,676.53% -5,611.87% -10,313.96% 0.00% -15,729.22% -7,289.05% -8,704.10% -13,120.00% 0.00% -4,325.68%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.00 0.00 0.01 0.02 0.35 0.33 0.36 0.38 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.03 0.03 0.02 0.03 0.04 0.10 1.79 1.81 1.90 1.95 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -65 -77 -72 -48 -49 -59 55 51 52 46 50
Invested Capital Turnover		 -0.04 -0.03 -0.02 -0.04 -0.05 -0.10 -13.22 59.43 76.94 -16.58 0.00
Increase / (Decrease) in Invested Capital		 -10 -23 -25 5.88 16 18 127 99 101 104 -4.89
Enterprise Value (EV)		 -165 -63 21 -58 -100 -134 -145 -110 -81 -27 191
Market Capitalization		 120 199 271 211 145 86 41 48 43 87 406
Book Value per Share		 $3.67 $3.09 $2.74 $2.68 $2.31 $1.90 $2.79 $2.44 $2.04 $1.82 $1.47
Tangible Book Value per Share		 $3.67 $3.09 $2.74 $2.22 $1.86 $1.50 $2.40 $2.04 $1.65 $1.43 $1.28
Total Capital		 219 185 178 222 196 161 240 210 185 163 267
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.34 3.76 1.94
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -284 -262 -250 -270 -245 -220 -186 -159 -124 -113 -215
Capital Expenditures (CapEx)		 3.27 0.98 0.54 0.27 -0.80 0.15 0.48 0.32 0.20 -0.14 0.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -14 -8.27 -12 -12 -125 -9.99 -11 -8.73 -13 -7.39
Debt-free Net Working Capital (DFNWC)		 153 159 184 184 186 64 155 145 124 104 127
Net Working Capital (NWC)		 153 159 184 184 186 64 155 145 116 101 125
Net Nonoperating Expense (NNE)		 7.78 8.76 6.15 6.88 6.87 9.97 -25 8.28 9.14 4.72 5.07
Net Nonoperating Obligations (NNO)		 -284 -262 -250 -270 -245 -220 -186 -159 -124 -113 -215
Total Depreciation and Amortization (D&A)		 3.35 -0.43 2.11 2.12 1.98 2.29 2.37 2.55 2.62 3.20 2.79
Debt-free, Cash-free Net Working Capital to Revenue		 -652.61% -608.05% -603.50% -591.92% -444.06% -1,897.45% -8.70% -9.31% -7.70% -11.74% 0.00%
Debt-free Net Working Capital to Revenue		 6,160.29% 7,120.72% 13,412.26% 9,026.20% 6,934.41% 975.40% 135.01% 127.25% 109.43% 95.54% 0.00%
Net Working Capital to Revenue		 6,160.29% 7,120.72% 13,412.26% 9,026.20% 6,934.41% 975.40% 135.01% 127.25% 102.07% 92.10% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.55) ($0.66) ($0.45) ($0.38) ($0.37) ($0.41) $0.89 ($0.38) ($0.40) ($0.25) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 59.45M 59.31M 62.30M 82.09M 84.70M 78.65M 86.02M 86.24M 86.46M 86.56M 193.47M
Adjusted Diluted Earnings per Share		 ($0.55) $0.00 $0.00 ($0.38) ($0.37) $0.00 $0.89 ($0.38) ($0.40) ($0.25) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 59.45M 59.31M 82.85M 82.09M 84.70M 78.65M 86.10M 86.24M 86.46M 86.56M 193.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.83M 64.82M 82.85M 84.72M 85.03M 86.05M 86.16M 86.39M 87.31M 179.72M 180.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -31 -22 -24 -24 -26 52 -24 -21 -14 -17
Normalized NOPAT Margin		 -16,850.14% -11,430.37% -2,563.31% -3,155.45% -3,078.67% -625.57% 47.56% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -21,708.11% -15,025.00% -3,281.99% -4,044.75% -3,948.67% -822.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Century Therapeutics (NASDAQ: IPSC) remains a development-stage biotech with no product revenue in the latest quarter, and its financial profile continues to be defined by heavy R&D spending, recurring operating losses, and a sizable cash and investment balance.

  • Strong liquidity remains intact: As of Q1 2026, Century Therapeutics held about $51.0 million in cash and equivalents and $83.8 million in short-term investments, plus $82.2 million in long-term investments.
  • Balance sheet still shows substantial asset coverage: Total assets were $326.6 million versus total liabilities of $61.8 million, leaving reported common equity of $264.7 million.
  • Debt burden is low: Short-term debt was only $1.9 million in Q1 2026, which helps reduce immediate financing risk.
  • Operating burn improved from the prior quarter: Net cash used in operations was $25.3 million in Q1 2026, better than $16.1 million in Q4 2025? actually slightly worse vs Q4 2025 is not correct; operational burn remained elevated but was roughly in line with prior periods after a very large financing inflow in Q1 2026.
  • Interest and investment income provides a cushion: Q1 2026 generated about $2.0 million in interest and investment income, helping offset losses modestly.
  • R&D spending remains the main use of cash: Research and development expense was $17.1 million in Q1 2026, compared with $19.7 million in Q4 2025 and $26.9 million in Q2 2025, showing some moderation but still very high.
  • The company is still not generating revenue: Q1 2026 revenue was $0, so profitability depends entirely on future clinical or partnership progress.
  • Capital structure has been volatile: Common stock on the balance sheet remains very large relative to retained earnings, reflecting a history of financing activities and accumulated losses.
  • Quarterly losses remain sizable: Q1 2026 net loss was $21.6 million, after a $19.2 million loss in Q4 2025 and $34.4 million loss in Q3 2025.
  • Cash declined quarter over quarter: Net change in cash and equivalents was a negative $11.3 million in Q1 2026, reflecting continued burn despite financing and investment activity.

Looking at the broader trend, Century Therapeutics has consistently posted negative operating cash flow over the last several years, with quarterly operating losses generally in the $20 million to $35 million range. The company did briefly report revenue in 2024, including a large first-quarter benefit, but that did not translate into sustained top-line growth. Since then, revenue has reverted to zero in recent quarters.

One notable positive is that the company has been able to preserve a meaningful liquidity position through investment holdings and financing actions. At the same time, investors should recognize that the business is still in an early-stage, cash-burning phase, and future shareholder value will likely depend on clinical progress and the need for additional capital.

07/05/26 07:41 PM ETAI Generated. May Contain Errors.

Century Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Century Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Century Therapeutics' net income appears to be on a downward trend, with a most recent value of -$9.58 million in 2025, falling from -$53.58 million in 2020. The previous period was -$126.57 million in 2024. Check out Century Therapeutics' forecast to explore projected trends and price targets.

Century Therapeutics' total operating income in 2025 was -$17.27 million, based on the following breakdown:
  • Total Gross Profit: $109.16 million
  • Total Operating Expenses: $126.43 million

Over the last 5 years, Century Therapeutics' total revenue changed from $0.00 in 2020 to $109.16 million in 2025, a change of 10,916,400,000.0%.

Century Therapeutics' total liabilities were at $64.77 million at the end of 2025, a 66.2% decrease from 2024, and a 93.8% increase since 2020.

In the past 5 years, Century Therapeutics' cash and equivalents has ranged from $27.21 million in 2020 to $84.27 million in 2022, and is currently $61.85 million as of their latest financial filing in 2025.

Over the last 5 years, Century Therapeutics' book value per share changed from -14.22 in 2020 to 1.82 in 2025, a change of -112.8%.


Related Companies

Financial statements for NASDAQ:IPSC last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel